10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
18 nov. 2024 10h20 HE
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Revolution Medicines to Participate in Upcoming Investor Conferences
05 nov. 2024 09h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial
30 oct. 2024 07h00 HE
|
SynOx Therapeutics Limited
Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1...
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
23 oct. 2024 07h00 HE
|
EvolveImmune
Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
21 oct. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein
10 oct. 2024 04h15 HE
|
ICPO Foundation
Die Parteien kooperieren weltweit im Bereich der therapeutischen klinischen Anwendungen der Nuklearmedizin in der Onkologie. 10. Oktober 2024 – Wiesbaden, Deutschland. Heute kündigte die...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
10 oct. 2024 04h15 HE
|
ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12 août 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
02 juil. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two...